Aristides Polyzos
Overview
Explore the profile of Aristides Polyzos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, et al.
Anticancer Res
. 2012 Sep;
32(9):4151-6.
PMID: 22993377
The combination of docetaxel, cisplatin and fluorouracil is considered to be one of the reference regimens for advanced gastric cancer, but due to its major myelotoxicity, its use in clinical...
2.
Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, et al.
Cancer Chemother Pharmacol
. 2011 May;
69(1):35-42.
PMID: 21590447
Purpose: To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of oral metronomic vinorelbine with capecitabine in patients with metastatic breast cancer (MBC). Patients And Methods: Escalated...
3.
Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, et al.
Breast Cancer Res Treat
. 2009 Jul;
119(1):95-104.
PMID: 19636702
A randomized multicenter phase III study was conducted to compare the sequential docetaxel followed by epirubicin/cyclophosphamide combination with that of FEC regimen as adjuvant chemotherapy in women with axillary node-positive...
4.
Polyzos A, Gogas H, Markopoulos C, Tsavaris N, Papadopoulos O, Polyzos K, et al.
Anticancer Res
. 2009 Jul;
29(7):2851-6.
PMID: 19596973
There is no standard treatment for breast cancer patients whose tumors have been exposed both to anthracyclines and taxanes. Oxaliplatin shows synergism with 5-fluorouracil (5-FU) and capecitabine is an oral...
5.
Polyzos A, Tsavaris N, Gogas H, Lagadas A, Polyzos K, Giannakopoulos K, et al.
Anticancer Res
. 2009 Jul;
29(7):2681-6.
PMID: 19596946
Background: The role of combination chemotherapy regimens in the management of ovarian cancer patients with tumors previously exposed to platinum compounds and paclitaxel has not yet been defined. The present...
6.
Panteleakou Z, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, et al.
Mol Med
. 2008 Dec;
15(3-4):101-14.
PMID: 19081770
Disseminated malignancy is the major cause of prostate cancer-related mortality. Circulating tumor cells (CTCs) are essential for the establishment of metastasis. Various contemporary and molecular methods using prostate-specific biomarkers have...
7.
Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, et al.
Oncology
. 2008 Nov;
76(1):36-41.
PMID: 19033714
Background: Oxaliplatin has become one of the major cytotoxic agents for the treatment of gastrointestinal tumors. As a result, several cases of the so-called oxaliplatin-associated hypersensitivity reaction have been documented....
8.
Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, et al.
Anticancer Res
. 2007 Jun;
27(3B):1645-51.
PMID: 17595790
Background: The role of combination chemotherapy regimens in the management of ovarian cancer patients with tumors previously exposed to platinum compounds and paclitaxel has not yet been defined. The present...
9.
Polyzos A, Tsavaris N, Kosmas C, Gogas H, Koutinos G, Nikiteas N, et al.
Clin Drug Investig
. 2007 May;
24(11):661-70.
PMID: 17523729
Objective: To investigate the efficacy and toxicity of gemcitabine administration followed by the combination of fluorouracil (5-FU) modulated by folinic acid in patients with advanced, symptomatic pancreatic cancer. The main...
10.
Polyzos A, Tsavaris N, Kosmas C, Polyzos K, Giannopoulos A, Felekouras E, et al.
Anticancer Res
. 2006 Nov;
26(5B):3749-53.
PMID: 17094396
The role of docetaxel in combination with cisplatin in the management of gastric cancer resistant to first-line chemotherapy has not yet been defined. This multicenter prospective phase II study evaluated...